Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Acro Biomedical (ACBM) Non-Current Debt (2020 - 2022)

Acro Biomedical has reported Non-Current Debt over the past 3 years, most recently at $78826.0 for Q4 2022.

  • Quarterly results put Non-Current Debt at $78826.0 for Q4 2022, up 280.05% from a year ago — trailing twelve months through Dec 2022 was $78826.0 (up 280.05% YoY), and the annual figure for FY2022 was $78826.0, up 280.05%.
  • Non-Current Debt for Q4 2022 was $78826.0 at Acro Biomedical, up from $20741.0 in the prior quarter.
  • Over the last five years, Non-Current Debt for ACBM hit a ceiling of $242951.0 in Q4 2020 and a floor of $20741.0 in Q4 2021.
  • Median Non-Current Debt over the past 3 years was $78826.0 (2022), compared with a mean of $114172.7.
  • Biggest five-year swings in Non-Current Debt: crashed 91.46% in 2021 and later soared 280.05% in 2022.
  • Acro Biomedical's Non-Current Debt stood at $242951.0 in 2020, then crashed by 91.46% to $20741.0 in 2021, then soared by 280.05% to $78826.0 in 2022.
  • The last three reported values for Non-Current Debt were $78826.0 (Q4 2022), $20741.0 (Q4 2021), and $242951.0 (Q4 2020) per Business Quant data.